Participants who have received any other investigational agents within the  weeks prior to enrollment; concurrent radiation therapy is not permitted, except palliative (limited-field) radiation therapy, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
Patients may not have had any prior systemic treatment for this malignancy (for example chemotherapy or somatostatin analogues); prior palliative radiation is permitted but radiated lesions may not be used for measurement
Subjects may receive palliative radiotherapy for symptomatic metastases prior to enrollment provided that there is at least one other non-irradiated lesion amenable to LCT at the time of enrollment.
Prior palliative radiation treatment for metastatic disease to be treated on the protocol (including radiopharmaceuticals)
Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.
The last dose of prior systemic therapy (e.g. chemotherapy, targeted therapy etc) or radiation therapy (with the exception of palliative radiotherapy) was received less than  days prior to the first day of treatment
Patients must have failed prior radiation therapy and must have an interval of greater than or equal to  days from the completion of radiation therapy to study entry; Note: patients with an indication for craniospinal radiotherapy (i.e., extensive leptomeningeal disease) but have refused palliative craniospinal radiotherapy are eligible
Concurrent anticancer treatment within  days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy]; immune therapy, or cytokine therapy, except for erythropoietin.
Palliative radiotherapy within  days before initiation of study treatment
Prior palliative radiation must have been completed at least  weeks prior to study entry
Participants who received prior non-central nervous system (CNS) directed palliative radiation therapy within  days of the date of study entry
Palliative radiation therapy may have been received but not within the  days prior to study treatment
Concurrent use of hypoglycemic agents or any systemic therapy for melanoma; palliative limited-field radiation therapy will be allowed
Completed palliative radiotherapy within  days of the first dose of study drug.
Radiotherapy within  weeks prior to therapy except palliative radiation to target organs other than primary tumor may be allowed up to  weeks prior to registration
Radiation therapy (palliative setting is allowed.): ? weeks
Anticancer treatment within  days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).
Concurrent therapy considered investigational\r\n* NOTE: patients must not be planning to receive any radiation therapy (except localized radiation for palliative care that must be completed prior to starting cycle , day )
Lesion that is amenable to palliative radiotherapy
At least  weeks after any prior palliative radiation (e.g. to focal metastatic lesion such as bone metastases) and recovery to =< grade  treatment-related toxicity
The last dose of previous therapy must have occurred at least  weeks prior to the start of study therapy; palliative radiotherapy is allowed up to  weeks before the first LMB- infusion
Anticancer treatment within  days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).
Radiotherapy: ? weeks (patients who receive palliative radiation for nontarget tumour lesions need not be subjected to this washout period and can be enrolled immediately)
Prior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least  weeks prior to treatment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within  weeks of first treatment are strongly encouraged to receive palliative radiotherapy prior to treatment
Patients who had undergone any palliative radiation within  weeks of study enrollment
Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Subjects who had major surgery or radiation therapy within  weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass.
Patient must not be a candidate for curative surgical or radiation therapy\r\n* NOTE: Palliative radiotherapy is permitted
If palliative radiotherapy administered, completion of palliative radiation therapy must be >=  weeks prior to cycle  day  of protocol therapy
At least one tumor for which palliative RT is considered appropriate standard therapy (cohort ); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort )
Prior palliative radiotherapy must have been completed at least  weeks prior to registration; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within  weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomization
Subjects requiring palliative radiation therapy at presentation
Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last  weeks
Concurrent therapy considered to be investigational; NOTE: patients must not be planning to receive any radiation therapy (except localized radiation for palliative care that must be completed prior to starting cycle , day )
Emergent need for palliative radiation
Palliative surgery and/or radiation treatment within  days prior to course  day  (CD) \r\n* Localized therapy of non-target lesions is allowed
The last dose of previous therapy must have occurred at least  weeks prior to the start of study therapy; palliative radiotherapy is allowed up to  weeks before the first LMB- infusion
Need for urgent palliative intervention (e.g., impending herniation)
Prior systemic therapy, radiation therapy, or surgery within the  days of starting study treatment; palliative radiotherapy to a limited filed or palliative cryoablation is allowed after consultation with the principal investigator, at any time during the study participation including screening
Palliative radiotherapy for bone metastasis/lesion within  weeks prior to the initiation of study treatment;
All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon >=  days before study entry
Patients must have histologically or cytologically confirmed advanced, incurable cancers of the esophagus, liver, stomach, small bowel, pancreas, bile duct, colon or rectum and be eligible to receive chest, abdominal and/or pelvic radiation therapy (RT) for palliation; documentation of this is required in physician note; concomitant systemic therapy is not allowed during administration of palliative RT; palliative RT can be considered for advanced primary tumors or metastatic disease as above
Radiotherapy within  weeks prior to enrollment, except as follows:\r\n* Palliative radiation to target organs other than chest may be allowed up to  weeks prior to enrollment, and\r\n* Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor-investigator prior to enrolling
Patient must be  weeks off any palliative radiation or craniospinal radiation
Palliative surgery and/or radiation treatment <  days prior to date of randomization.
Metastatic cancer requiring palliative radiation therapy
Palliative radiation is allowed to sites that will not be used to measure response during this study
Any concurrent therapy for cancer, radiation, or surgery within  weeks, except for minor palliative intent (this is to be discussed with sponsor)
Patients must have at least one lesion not previously irradiated (and not within a previously irradiated field) for which palliative radiation to the abdomen and/or pelvis is potentially indicated and could be safely delivered at the radiation doses specified in this protocol; this lesion must not be within the central nervous system (CNS) (brain or spinal cord), bone or liver, and must not require urgent or emergent palliative radiation given the timing of radiation specified on this protocol; furthermore, this lesion must be located in the abdomen or pelvis and measure at least  cm (minimum dimension) and no greater than  cm (maximum dimension); palliative radiotherapy would entail involved-field radiotherapy to a single lesion or region to encompass gross disease; whole-abdomen radiotherapy would not be permitted; patients who received prior vaginal brachytherapy would be permitted to receive palliative pelvic radiation; in the expansion cohort at the maximum tolerated dose (MTD), this lesion must not be the only measurable lesion so that it is possible to determine the response rate outside of the radiation treatment field
Palliative surgery and/or radiation treatment less than  weeks prior to initiation of study treatment.
Prior anti-cancer therapy or radiation therapy within  weeks prior to enrolment. Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been completed at least  days prior to enrolment and no significant toxicity are expected.
Prior radiotherapy within  weeks of study treatment. A -week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.
Localized palliative radiation therapy is allowed for symptom management if completed >=  days prior to randomization
Any radiotherapy within  weeks except palliative stereotactic body radiation therapy (SBRT) within  weeks
Radiation therapy in the last  days; palliative radiation to a localized area without residual toxicity requires a washout of greater than  days
Palliative radiotherapy (?  fractions) within  weeks prior to Screening
Patients must be candidates for palliative radiation
Palliative radiotherapy for bone metastases <  weeks prior to cycle , day 
Prior palliative radiation therapy to bony metastases is allowed; there should be a minimum of  days between the end of radiation treatment and start of study treatment
Subjects who received palliative radiotherapy ? weeks of study drug initiation.
discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least  weeks prior to randomization and recovered from the acute effects of therapy
Prior palliative radiation therapy to bony metastases will be allowed; there should be minimum of  days between the end of radiation treatment and start of study treatment
Palliative radiation therapy to bony metastases </=  weeks before study treatment
Requires urgent palliative intervention for primary disease.
Completed palliative radiotherapy within  days of the first dose of study medication.
Palliative radiation therapy within  weeks of Day  of trial drug treatment
Subject may have  course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least  weeks prior to day ;
Any cancer therapy in the last  weeks or limited palliative radiation < weeks
Palliative radiation to target organs other than chest may be allowed up to  weeks prior to study treatment, or
Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
Surgery or definitive radiation within the four weeks prior to D of treatment under this protocol (there is no restriction on timing of palliative radiation)
The subject has had palliative radiation therapy to bone metastases within  days prior to the Day  visit (side effects from radiation must be resolved).
No prior palliative chemotherapy
Presence of metastatic disease that, in the opinion of investigators, would require palliative treatment within  weeks of enrollment
Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapy
Prior palliative radiotherapy to metastases
Patients may receive local palliative radiation therapy immediately before or during the treatment if the radiation therapy is not delivered to the sole target lesions
Anticancer treatment within  days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy
There should also be a minimum of  weeks from any prior radiotherapy except for palliative bone directed therapy
Need for urgent palliative intervention for primary disease (e.g., impending herniation).
Patients who have received radiotherapy =<  weeks prior to registration, with the exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =<  are not eligible for participation\r\n* Note: any lesions treated with radiation therapy cannot be used in disease assessment
Palliative radiation must have been completed  weeks prior to the initiation of study therapy.
At least one tumor for which palliative RT is considered appropriate standard therapy
At least one tumor for which palliative RT is considered appropriate standard therapy (cohort ); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort )
Patients who have received palliative radiotherapy within  weeks of study entry.
Radiation oncologist determines that the patient is medically able to undergo palliative radiation therapy and plans to treat the patients target lesions with one fraction of high dose palliative radiation therapy utilizing the Scan-Plan-Quality Analysis (QA)-Treat STAT RAD workflow
Palliative radiation within  weeks.
Radiotherapy, chemotherapy or immunotherapy within  weeks, or palliative radiation to bone metastases within  days of administration of cycle , day 
Palliative radiotherapy must have been discontinued  week prior to treatment in this study
No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Prior palliative radiation therapy to bone sites is allowed as long as it is completed more than two weeks ago
Rapidly progressing cancer likely to require palliative systemic intervention within  weeks after study entry
Any major surgery, chemotherapy or immunotherapy within the last  days (limited palliative radiation is allowed ?  weeks);
Patients receiving palliative radiation will be eligible after a wash-out period of  weeks between finishing radiation and initiation of study drugs; palliative radiation will not be allowed during cycle  of treatment but is permitted in this study during following cycles as long as there are evaluable lesions that are not being irradiated
No radiotherapy within  weeks: exception: patients may receive palliative low dose radiotherapy ( Gy or less) for lesions outside the lung at the discretion of the treating physician; palliative radiotherapy could be given before aerosol treatment is started if necessary
No concomitant anti-cancer chemotherapy or other systemic drugs; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
At least one measurable site of disease (>= . cm) outside of the planned palliative radiation therapy field
Women with planned treatment of palliative radiotherapy
Palliative radiation to bony metastases within  weeks prior to initiation of ipatasertib
Patients may receive palliative radiation therapy before or during treatment on protocol, provided that there is measurable or evaluable disease out of the radiation field; patients may receive palliative radiation therapy, if needed,  hours after last dose of investigational drug; in addition patients may be enrolled on trial seven days following palliative radiation; we will closely monitor for the appearance of radiation recall reactions; hormonal therapy may continue in patients who have been on such treatment for three months or longer
Radiation therapy within the last  weeks prior to randomization(with exception of palliative radiotherapy)
Prior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least  weeks prior to enrollment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within  weeks of enrollment are strongly encouraged to receive palliative radiotherapy prior to enrollment
Palliative radiotherapy is allowed up to  weeks before the first RO infusion; palliative  Gy radiotherapy is allowed during therapy.
Patients cannot receive concomitant radiation therapy at enrollment; while on protocol limited palliative radiotherapy extending over a small bone marrow field (%) is allowed
Prior palliative or curative radiotherapy must be completed at least  days prior to randomization
Localised palliative radiotherapy Prior chemotherapy must be >  months before screening
Palliative radiation, including whole brain radiation therapy (WBRT), is allowed prior to enrollment as long as it is completed >  weeks from initiation of study treatment, and provided patient has recovered from treatment toxicities to =< grade 
Palliative radiation to bone metastases within  weeks prior to Day 
Palliative radiotherapy within  weeks prior to first dose of study-drug treatment in Cycle 
An immediate need for palliative radiotherapy or systemic corticosteroid therapy.
Palliative surgery or radiotherapy.
Received palliative/focal radiotherapy within  weeks of first dose of study treatment.
Prior radiation therapy completed <  weeks or single fraction of palliative radiotherapy <  days prior to first dose of KPT- (selinexor)
Palliative surgery and/or radiation treatment within  days prior to date of randomization.
Palliative radiation therapy to metastatic sites of disease <  weeks prior to study day .
within  weeks prior to the first dose of KTN in the case of palliative radiation therapy.
Palliative surgery and/or radiation treatment less than  weeks to randomization.
Palliative radiation within  weeks prior to Day .
An immediate need for palliative radiotherapy or systemic corticosteroid therapy
Therapeutic or palliative radiation therapy within  days of starting treatment
Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Patient is receiving concurrent radiation therapy to treat primary disease with curative intent. (Note that palliative radiotherapy is allowed as long as there is no evidence of progressive disease.)
Received local palliative radiation therapy < days prior to the first dose of study medication
Palliative radiotherapy is not permitted throughout the study period;
No concomitant anti-cancer chemotherapy or other systemic drugs; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
Therapeutic or palliative radiation therapy within  weeks prior to enrollment
The participant has completed prior chemotherapy and/or radiotherapy with curative intent at least  weeks prior to the administration of the first dose of study therapy. Participants that have received palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible
Prior systemic therapy, radiation therapy, or surgery within  days of starting study treatment; palliative radiotherapy to a limited field or palliative cryoablation is allowed after consultation with the principle Investigator, at any time during the study participation including screening
Palliative radiation treatment (e.g., pain control, bony lesions at risk of fracture) completed =<  weeks of starting study treatment; patient will be eligible if palliative radiotherapy is completed >  weeks from the start of study treatment and has recovered from radiotherapy toxicities
All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), and surgery, >=  days before study entry
Undergoing only palliative (not curative) radiation treatment
Patients already receiving palliative care
PATIENT EXCLUSION: Palliative performance scale rating < 
Palliative surgery and/or radiation treatment within  days prior to date of screening visit.
New systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
Patients already receiving palliative care
(Physician participation) a palliative medicine specialist
Palliative Performance Scale (PPS) of  or higher at recruitment
Patient is planned to receive hypofractionated palliative radiation =<  fractions
Previous radiotherapy or palliative surgery to the painful site that is planned for treatment
Receiving palliative radiation therapy
At the time of day  of the study, patients must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, radiation therapy or major surgery (requiring general anesthesia) at least  days before administration of the first dose of nivolumab; patients undergoing minor surgical procedures and biopsies that do not require general anesthesia may begin receiving study therapy if sufficiently recovered as determined by the treating investigator; patients may have received prior focal radiotherapy for palliation of an isolated site of disease, which must be completed at least  days prior to day  of the study; palliative (limited-field) radiation therapy is permitted during treatment with study drug(s), if all of the following criteria are met: \r\n* The lesion being considered for palliative radiation is not a target lesion\r\n* Radiation treatment is administered  weeks or greater after their first dose of study drug
Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) =<  weeks prior to study drug administration date
Treatment with palliative or pre-operative radiation
Patients who receive RT or CRT with palliative intent
Patient receiving palliative radiation therapy (defined as less than  Gy)
Prior radiotherapy within  weeks of study treatment. A -week washout period is permitted for palliative radiation to non- central nervous system (CNS) disease with medical monitor approval.
> week since palliative RT
Patients treated with radiation for palliative intent
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment to the site of bone and other metastasis.
Palliative radiotherapy within  weeks prior to first dose of study drug treatment in Cycle 
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment.
